Few reasons I like it… I really like the data and real-world...

Few reasons I like it… I really like the data and real-world evidence approach they’ve taken with this, much more upside than just being a patient access clinic. Anonymous, high quality data (that would stand up with a regulator) is collected from the fee-paying patients visiting Emerald’s trained doctors/cannabinoid specialists.

The lack of clinical evidence is currently holding the industry back and limiting patient access (Elixinol’s product claims issue a great example) and Emerald is positioned nicely to address this. Their data is going to be valuable to producers, regulators, insurers, patients etc and they’ve already shown this in the deal with Spectrum, apparently other big name deals in the pipeline too.

Real world evidence model of drug approval is gaining momentum and a focus of the FDA. Worth looking at a company called Flatiron who did this well for other drugs, Flatiron was recently acquired by Roche.

The four Emerald clinics opened to date have ~1k active patients and are bringing in small revenues already, which the company breaks even on before the upside of the data deals. New clinics to be opened both here and in the UK. The MD Michael Winlo has impressive background and proposed director Sir Prof John Tooke will be crucial as they enter the UK. Lead manager has excellent track record in the sector too, shareholders on board already include Canopy, Cann Group, CB1 Capital, local institutions.